Lodestar

HIMS

Hims & Hers Health, Inc.
NYSEServices-Offices & Clinics of Doctors of MedicineLatest fiscal year ended Dec 31, 2025

Hims & Hers Health, Inc. reported revenue of $2.35B in its most recent fiscal year, up 59.0% on the year before. It kept 5.5% of that as net income, and generated $57.41M of free cash flow. Figures below are compared against other companies classified under Services-Offices & Clinics of Doctors of Medicine.

Grades vs. industry

Growth
B+76/100
Ranked against 6 peers using 4 metrics.
Profitability
B+71/100
Ranked against 5 peers using 7 metrics.

Growth

MetricCompanyIndustry medianRank
Revenue growth (YoY)
Latest fiscal year revenue vs. the year before.
59.0%13.2%1 / 9
Revenue growth (3y)
Annualized revenue growth over three fiscal years.
64.5%9.7%1 / 6
Revenue growth (5y)
Annualized revenue growth over five fiscal years.
73.6%20.6%1 / 6
EPS growth (YoY)
Diluted EPS vs. the prior fiscal year.
-3.8%——
EPS growth (3y)
Annualized diluted EPS growth over three fiscal years.
Not reported——
EPS growth (5y)
Annualized diluted EPS growth over five fiscal years.
Not reported——
Free cash flow growth (YoY)
Operating cash flow less capital expenditure, vs. prior year.
-71.0%-29.6%5 / 6
Free cash flow growth (3y)
Annualized free cash flow growth over three fiscal years.
Not reported——

top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.

“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.

Profitability

MetricCompanyIndustry medianRank
Gross margin
Gross profit as a share of revenue. Often unreported.
73.8%73.3%2 / 5
Operating margin
Operating income as a share of revenue.
4.5%-5.6%3 / 8
Net margin
Net income as a share of revenue.
5.5%-7.7%3 / 9
Free cash flow margin
Free cash flow as a share of revenue.
2.4%2.4%5 / 9
Return on equity
Net income divided by shareholder equity.
23.7%14.1%3 / 8
Return on assets
Net income divided by total assets.
6.0%0.0%3 / 10
Return on invested capital
After-tax operating profit over debt plus equity less cash.
33.8%-6.7%1 / 7

top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.

“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.

Financial health

MetricCompanyIndustry medianRank
Debt to equity
Total debt divided by shareholder equity.
Not reported——
Current ratio
Current assets over current liabilities.
1.90x1.28x3 / 10
Quick ratio
Current assets excluding inventory, over current liabilities.
1.70x1.22x3 / 10
Interest coverage
Operating income divided by interest expense.
Not reported-1.90x—
Net debt to EBITDA
Net debt over derived EBITDA. EBITDA is not a GAAP tag; it is computed.
-3.61x——

top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.

“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.

Debt figures can be understated where a filer splits borrowings across XBRL tags this site does not match.

Insider activity

Trades reported by officers, directors and 10% shareholders on SEC Form 4. None of the last 40 reported transactions were open-market purchases — grants, option exercises and sales make up the majority of insider filings at most companies.

DateInsiderTransactionSharesPriceValue
Oct 14, 2026
Boughton Soleil
Chief Legal Officer
Open-market sale3,461$29.06$100.6K
Oct 1, 2026
Okupe Oluyemi
Chief Financial Officer
Open-market sale2,000$29.70$59.4K
Sep 30, 2026
Boughton Soleil
Chief Legal Officer
Open-market sale3,461$29.17$101.0K
Sep 22, 2026
Okupe Oluyemi
Chief Financial Officer
Open-market sale29,277$29.95$876.8K
Sep 22, 2026
Okupe Oluyemi
Chief Financial Officer
Option exercise14,000$5.01$70.1K
Sep 22, 2026
Okupe Oluyemi
Chief Financial Officer
Option exercise(derivative)14,000$0.00$0.00
Sep 17, 2026
Okupe Oluyemi
Chief Financial Officer
Open-market sale12,313$28.82$354.9K
Sep 16, 2026
Boughton Soleil
Chief Legal Officer
Open-market sale6,236$27.86$173.7K
Sep 15, 2026
Chi Michael
Chief Operating Officer
Open-market sale14,027$28.39$398.2K
Sep 15, 2026
Elshenawy Mohamed
CTO
Open-market sale7,954$28.39$225.8K
Sep 2, 2026
Boughton Soleil
Chief Legal Officer
Open-market sale3,458$28.33$98.0K
Aug 27, 2026
Dudum Andrew
Chief Executive Officer
Other977,566$0.00$0.00
Aug 25, 2026
Dudum Andrew
Chief Executive Officer
Gift463,289$0.00$0.00
Aug 19, 2026
Boughton Soleil
Chief Legal Officer
Open-market sale25,111$27.55$691.8K
Aug 19, 2026
Okupe Oluyemi
Chief Financial Officer
Open-market sale4,938$29.99$148.1K
Aug 19, 2026
Okupe Oluyemi
Chief Financial Officer
Option exercise4,938$5.01$24.7K
Aug 19, 2026
Okupe Oluyemi
Chief Financial Officer
Option exercise(derivative)4,938$0.00$0.00
Aug 18, 2026
Autor Deborah M.
Chief Policy Officer
Open-market sale16,773$27.85$467.1K
Aug 17, 2026
Okupe Oluyemi
Chief Financial Officer
Open-market sale9,388$27.89$261.8K
Aug 17, 2026
Okupe Oluyemi
Chief Financial Officer
Option exercise9,388$5.01$47.0K
Aug 17, 2026
Okupe Oluyemi
Chief Financial Officer
Option exercise(derivative)9,388$0.00$0.00
Aug 14, 2026
Elshenawy Mohamed
CTO
Withheld for tax95,798$28.15$2.70M
Aug 14, 2026
Dudum Andrew
Chief Executive Officer
Withheld for tax78,859$28.15$2.22M
Aug 14, 2026
Chi Michael
Chief Operating Officer
Withheld for tax47,702$28.15$1.34M
Aug 14, 2026
Okupe Oluyemi
Chief Financial Officer
Withheld for tax36,437$28.15$1.03M

A dash under price or value means none was reported, which is normal for grants and gifts — it does not mean the shares were free. Option exercises and awards are compensation arriving on a schedule, not a judgement about the stock.

Annual financials

Fiscal year2025202420232022202120202019
Revenue$2.35B$1.48B$872.00M$526.92M$271.88M$148.76M$82.56M
Gross profit$1.73B$1.17B$714.95M$408.72M$204.49M$109.45M$44.60M
Operating income$105.61M$61.90M-$29.45M-$68.70M-$115.04M-$15.14M-$74.41M
Net income$128.37M$126.04M-$23.55M-$65.68M-$107.66M-$18.11M-$72.06M
EPS (diluted)$0.51$0.53-$0.11-$0.32-$0.58n/cn/c
Operating cash flow$300.01M$251.08M$73.48M-$26.53M-$34.41M-$2.48M-$74.87M
Capital expenditure$242.60M$52.80M$26.50M$7.20M———
Free cash flow$57.41M$198.28M$46.98M-$33.73M———
Total assets$2.15B$707.54M$441.19M$366.34M$420.58M$118.70M$204.77M
Shareholder equity$540.93M$476.72M$344.03M$311.74M$334.62M-$146.87M-$139.79M
Cash$228.62M$220.58M$96.66M$46.77M$71.78M$27.34M$1.51M

A dash means the figure was not tagged in that year’s filing. It does not mean zero. Figures reflect the most recent filing covering each period, so restated years show their restated values.

n/c marks per-share figures that are not comparable. Companies report each year as their filings stated it, and an annual report restates only its two prior years — so after a stock split, older years remain on the pre-split share count. Totals above are unaffected.

Source

Figures come from Hims & Hers Health, Inc.’s filings with the SEC, as submitted in XBRL. The most recent annual figures are from a 10-K filed Feb 23, 2026. View filings on EDGAR.

Not financial advice. This page presents figures reported to the SEC and compares them with other companies sharing an industry classification. It is not a recommendation to buy or sell anything, and the grades cannot capture everything that matters about a business. Industry classifications are coarse, filings are self-reported, and some figures are missing or understated where companies tag them in ways this site does not match. Do your own research.